{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T21:33:10Z","timestamp":1775079190415,"version":"3.50.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":204,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/j.lrr.2024.100474","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T20:17:22Z","timestamp":1721852242000},"page":"100474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9985-3403","authenticated-orcid":false,"given":"Jeffrey","family":"Baron","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manu R.","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunice S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2024.100474_bib0001","unstructured":"Why don't Jehovah's witnesses accept blood transfusions? April 24, 2024, 2024. https:\/\/www.jw.org\/en\/jehovahs-witnesses\/faq\/jehovahs-witnesses-why-no-blood-transfusions\/."},{"issue":"7277","key":"10.1016\/j.lrr.2024.100474_bib0002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1136\/bmj.322.7277.37","article-title":"Bioethical aspects of the recent changes in the policy of refusal of blood by Jehovah's witnesses","volume":"322","author":"Muramoto","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.lrr.2024.100474_bib0003","doi-asserted-by":"crossref","unstructured":"Haddad F.G., Sawyers J., Short N.J. Treatment de-escalation in Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: the emerging role of chemotherapy-free regimens. Ther. Adv. Hematol. 2023;14:20406207231151294. doi:10.1177\/20406207231151294.","DOI":"10.1177\/20406207231151294"},{"issue":"Supplement 1","key":"10.1016\/j.lrr.2024.100474_bib0004","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-120029","article-title":"A phase II study of Dasatinib and Dexamethasone as primary therapy followed by transplantation for adults with newly diagnosed Ph\/BCR-ABL1-positive acute lymphoblastic leukemia (Ph+ ALL): final results of alliance\/CALGB study 10701","volume":"132","author":"Wieduwilt","year":"2018","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.lrr.2024.100474_bib0005","doi-asserted-by":"crossref","first-page":"6521","DOI":"10.1182\/blood-2011-05-351403","article-title":"Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"118","author":"Foa","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.lrr.2024.100474_bib0006","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/bloodadvances.2021004821","article-title":"INCB84344-201: ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia","volume":"6","author":"Martinelli","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.lrr.2024.100474_bib0007","first-page":"e24","article-title":"Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.lrr.2024.100474_bib0008","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","article-title":"Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia","volume":"61","author":"Gokbuget","year":"2020","journal-title":"Leuk. Lymphoma"},{"issue":"10","key":"10.1016\/j.lrr.2024.100474_bib0009","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/bmt.2008.5","article-title":"SCT in Jehovah's witnesses: the bloodless transplant","volume":"41","author":"Sloan","year":"2008","journal-title":"Bone Marrow Transplant."},{"issue":"15","key":"10.1016\/j.lrr.2024.100474_bib0010","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1200\/JCO.2014.57.9912","article-title":"Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's witnesses","volume":"33","author":"Ford","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.lrr.2024.100474_bib0011","doi-asserted-by":"crossref","first-page":"S379","DOI":"10.1016\/j.bbmt.2019.12.168","article-title":"Successful anti-CD 19 CAR-T cell therapy in jehovah witness patient with relapsed refractory B-ALL","volume":"26","author":"Leal","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"issue":"1","key":"10.1016\/j.lrr.2024.100474_bib0012","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s13054-019-2511-9","article-title":"Interventions to prevent iatrogenic anemia: a Laboratory Medicine Best Practices systematic review","volume":"23","author":"Whitehead","year":"2019","journal-title":"Crit. Care"},{"issue":"5","key":"10.1016\/j.lrr.2024.100474_bib0013","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1111\/trf.15778","article-title":"A case study of 10 patients administered HBOC-201 in high doses over a prolonged period: outcomes during severe anemia when transfusion is not an option","volume":"60","author":"Zumberg","year":"2020","journal-title":"Transfusion"},{"issue":"9","key":"10.1016\/j.lrr.2024.100474_bib0014","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1080\/10428194.2019.1577414","article-title":"High-dose chemotherapy without transfusion for Philadelphia chromosome negative B-cell acute lymphoblastic leukemia in two Jehovah's Witnesses patients: a feasible option in the age of hematopoietic growth factors","volume":"60","author":"Perol","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.lrr.2024.100474_bib0015","article-title":"The treatment of acute lymphoblastic leukemia in Jehovah's Witnesses and patients who cannot accept blood products","volume":"18","author":"Nguyen","year":"2022","journal-title":"Leuk. Res. Rep."},{"issue":"3","key":"10.1016\/j.lrr.2024.100474_bib0016","doi-asserted-by":"crossref","first-page":"7083","DOI":"10.4081\/hr.2017.7083","article-title":"Managing acute promyelocytic leukemia in patients belonging to the Jehovah's Witness congregation","volume":"9","author":"Jillella","year":"2017","journal-title":"Hematol. Rep."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048924000645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T20:37:33Z","timestamp":1733431053000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048924000645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":16,"alternative-id":["S2213048924000645"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100474","relation":{},"ISSN":["2213-0489"],"issn-type":[{"value":"2213-0489","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in Jehovah's witness patients","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2024.100474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100474"}}